Velcade Injection, Powder, Lyophilized, For Solution
Product Images NDC 63020-049

10 FDA label images from Takeda Pharmaceuticals America, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Velcade (NDC 63020-049). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Takeda Pharmaceuticals America, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Velcade 1)

Chemical Structure (Velcade 1)
Chemical structure of bortezomib, the active ingredient in VELCADE injection. The diagram shows the molecular structure with boron atoms, amide bonds, and a phenyl ring characteristic of bortezomib's chemical composition.*
FDA Label Image

Figure 1 (Velcade 2)

Figure 1 (Velcade 2)
A survival curve chart comparing the percentage of patients over time (in months) for two treatment groups labeled Vc-MP and MP. The chart includes patient counts at risk for each group at various time points and a p-value from a log-rank test indicating statistical significance.*
FDA Label Image

Figure 2 (Velcade 3)

Figure 2 (Velcade 3)
A Kaplan-Meier survival curve chart showing the percentage of patients over time in months. It compares two treatment groups labeled Vc-MP and MP, with Vc-MP represented by a red dotted line and MP by a solid blue line. The chart includes a legend, p-value indication (p < 0.05), and a table below showing the number of patients at risk at various time points for each group.*
FDA Label Image

Figure 3 (Velcade 4)

Figure 3 (Velcade 4)
A Kaplan-Meier survival curve comparing the proportion of patients over time (days) between two treatment groups: Bortezomib and Dexamethasone. The graph shows patient survival probabilities declining across approximately 450 days, with Bortezomib maintaining a higher proportion of patients compared to Dexamethasone. The chart includes sample sizes at various time points and a reported p-value from a log-rank test (p < 0.0001).*
FDA Label Image

Figure 4 (Velcade 5)

Figure 4 (Velcade 5)
A Kaplan-Meier survival curve comparing the proportion of patients over time (days) receiving bortezomib versus dexamethasone. The graph shows patient survival declining over approximately 450 days, with bortezomib (blue line) maintaining a higher proportion of patients compared to dexamethasone (red line). Patient numbers at specific time points and a p-value from a log-rank test are included.*
FDA Label Image

Figure 5 (Velcade 6)

Figure 5 (Velcade 6)
A Kaplan-Meier survival curve chart depicting percentage of patients over time (months) for two groups: VcR-CAP and R-CHOP. The vertical axis represents the percentage of patients, and the horizontal axis shows time in months up to 60. The chart includes a log-rank test p-value of less than 0.001, with a table below indicating subjects at risk over different time points for each group.*
FDA Label Image

Figure 6 (Velcade 7)

Figure 6 (Velcade 7)
This is a Kaplan-Meier survival curve comparing the percentage of subjects alive over time (months from randomization) for two treatment groups: VcR-CAP (solid line) and R-CHOP (dashed line). The graph includes a hazard ratio of 0.66 (95% CI: 0.51, 0.85) indicating relative survival differences. Number of subjects at risk is shown below the x-axis for each group at various time points up to 108 months.*
FDA Label Image
FDA Label Image

Image Description (Velcade 8 Cam)

Image Description (Velcade 8 Cam)
VELCADE (bortezomib) for Injection 3.5 mg/vial powder, lyophilized, single-dose vial for intravenous or subcutaneous use. The label includes storage instructions to keep the product at 25°C (77°F) with permitted excursions, protect from light, and discard unused portion. Distributed by Takeda Pharmaceuticals America, Inc.*
FDA Label Image

Image Description (Velcade 9)

Image Description (Velcade 9)
Box packaging label for VELCADE (bortezomib) for Injection, 3.5 mg/vial, lyophilized powder for solution by Takeda Pharmaceuticals America, Inc. Intended for intravenous or subcutaneous use, with reconstitution information and storage conditions provided. The label displays the NDC 63020-049-01 and includes a dosage and reconstitution guide.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.